Avalo Therapeutics, Inc.
HealthcareNASDAQ:AVTX · NASDAQ Capital Market
+$1.09 today
Vol 1.10M · Avg 1.57M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+204.96%
Period High
$22.87
Period Low
$4.47
Latest
$14.76
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Coherus Oncology, Inc.
NASDAQ:CHRS
$171.37M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
What is the latest AVTX filing?
The latest filing shown is 8-K dated Jun 12, 2026.
How many recent filings does AVTX have?
Intrinsic Alpha currently shows 20 recent filings for AVTX.
Explore More
Continue the stock analysis
Jump to another research area for this company.